Autosomal-recessive cerebellar ataxias (ARCAs) comprise a heterogeneous group of rare degenerative and metabolic genetic diseases that share the hallmark of progressive damage of the cerebellum and its associated tracts. This Review focuses on recent translational research in ARCAs and illustrates the steps from genetic characterization to preclinical and clinical trials. The emerging common pathways underlying ARCAs include three main clusters: mitochondrial dysfunction, impaired DNA repair, and complex lipid homeostasis. Novel ARCA treatments might target common hubs in pathogenesis by modulation of gene expression, stem cell transplantation, viral gene transfer, or interventions in faulty pathways. All these translational steps are addressed in current ARCA research, leading to the expectation that novel treatments for ARCAs will be reached in the next decade.
Autosomal-recessive cerebellar ataxias (ARCAs) comprise a heterogeneous group of rare degenerative and metabolic genetic diseases that share the hallmark of progressive damage of the cerebellum and its associated tracts. This Review focuses on recent translational research in ARCAs and illustrates the steps from genetic characterization to preclinical and clinical trials. The emerging common pathways underlying ARCAs include three main clusters: mitochondrial dysfunction, impaired DNA repair, and complex lipid homeostasis. Novel ARCA treatments might target common hubs in pathogenesis by modulation of gene expression, stem cell transplantation, viral gene transfer, or interventions in faulty pathways. All these translational steps are addressed in current ARCA research, leading to the expectation that novel treatments for ARCAs will be reached in the next decade.
ARCA: A Rapidly Growing Number of Genes and Expanding Phenotypic Spectra
Autosomal-recessive cerebellar ataxias (ARCAs) are a heterogeneous group of rare progressive neurodegenerative genetic diseases. They share the clinical feature of predominant ataxia resulting from progressive damage to the cerebellum and/or its associated afferent tracts (Anheim et al., 2012; Synofzik and Né meth, 2018) . In most ARCAs, the neurodegenerative process is not limited to these defining core structures but includes several additional neurologic systems (e.g., retina, cerebral cortex, basal ganglia, corticospinal tracts, and peripheral nerves) as well as non-neurologic tissues (e.g., heart, pancreas, muscle), thus leading to severe, complex multisystemic phenotypes, often starting before the age of 40 (Synofzik and Né meth, 2018) . ARCAs are molecularly defined by the underlying mutated gene. More than 92 autosomal-recessive diseases present with ataxia as a predominant and/or consistent clinical feature, and in an additional 89 autosomal-recessive diseases, ataxia is at least part of the phenotypic spectrum ( Figure 1) (Rossi et al., 2018) . This genetic pleiotropy is further expanded by the growing number of autosomal-dominant ataxia genes that are now recognized to also cause autosomal-recessive ataxia in case of biallelic inheritance, often giving rise to very severe, early-onset recessive ataxia syndromes (e.g., AFG3L2/SCA 28, SPTBN2/ SCA5, ITPR1/SCA29, OPA1) (Synofzik and Né meth, 2018) .
The recent progress in next-generation sequencing (NGS) has also allowed us to revise the relative frequencies of ARCA genotypes and to appreciate novel phenotypes. While Friedreich's ataxia (FA) is still by far the most common ARCA, accounting for up to 25% of all ARCAs, it is now increasingly acknowledged that autosomal-recessive spastic ataxia of Charlevoix-Saguenay (ARSACS; gene: SACS) and Spectrin repeat-containing nuclear envelope protein (SYNE1) ataxia, which were long thought to be largely restricted to specific French-Canadian populations comprise relatively frequent ARCAs with a worldwide distribution (Coutelier et al., 2018; Fogel et al., 2014; Synofzik et al., 2016; Synofzik et al., 2013) . Furthermore, spastic paraplegia type 7 (SPG7), which has been considered for many years only as a major cause of hereditary spastic paraplegia (HSP), is now appreciated as a frequent cause of ARCA (Coutelier et al., 2018; Pfeffer et al., 2015) . Yet, each of these genes still accounts for only 2%-5% of all ARCAs (Synofzik and Né meth, 2018) . Despite all progress with NGS, z50% of patients with the clinical suspicion of ARCA remain without a molecular diagnosis. This may reflect not only new ARCA genes but also mutations in established genes that escape current diagnostic strategies such as deep intronic mutations, mutations in regulatory regions, epigenetic changes, gene dosage effects, or digenic modes of inheritance (for examples, see Bonifert et al., 2014; Minnerop et al., 2017) .
Except for FA, which results from a non-coding repeat expansion, almost all other ARCA mutations identified so far constitute conventional mutations. These are identified by current NGS approaches, thus yielding a ''NGS-first approach'' as the most comprehensive diagnostic strategy for clinical practice. This should become state of the art in the diagnostic workup of ARCA patients if FA is unlikely and no other ARCA candidate is deemed directly obvious (e.g., by changes in plasma biomarkers exemplified in Tables 1, 2, and 3) (Synofzik and Né meth, 2018) .
From Phenotypes to Mechanisms
ARCAs often present with multisystemic phenotypes showing a wide inter-and intra-familial variability (e.g., POLG ataxia; Synofzik et al., 2012) , with phenotypic spectra dramatically expanding for many ARCAs over the last 6 years (for examples, see SYNE1 [Synofzik et al., 2016] and PNPLA6 [Synofzik et al., 2014] ). Current phenotypically driven classifications of ARCAs are based on ataxia or non-ataxia features (Anheim et al., 2012; Renaud et al., 2017) but are of only limited help for the diagnostic strategy and a systematic understanding of ARCAs. The next step is to move toward a mechanistically inspired approach based on the underlying gene and the underlying molecular mechanism and pathways, which might even be shared across several ARCAs. This approach can be used both for grouping ARCAs (as done in this review) and to try to find common strategies for therapies. Identification of the underlying genetic variant is the first step toward molecular delineation of key pathophysiological mechanisms and pathways underlying each ARCA (see Figure 2 ). This approach thereby moves on from simple classifications by the underlying gene and primary gene function toward common molecular pathomechanisms and cellular pathways, which might be shared across several ARCAs, such as disturbed mitochondrial protease processing, impaired single-strand DNA repair, or defective phospholipid remodeling (see sections 2.1-2.3). It thus allows us to create new convergences at the functional level rather than having an ever-expanding pleiotropy of diverse ARCA genes as illustrated in Figure 2 (genes C, D and E).
This focus on pathomechanisms opens a new perspective for translational ARCA research and will allow us to prioritize research on molecular pathways shared across several ARCAs. For example, compounds leading to increased antioxidant gene expression (e.g., omaveloxolone/RTA 408, acting via activation of the antioxidative transcription factor Nrf2) might serve as a pharmacological principle applicable to several ARCAs with primary or secondary oxidative damage (see section 2.1). Another example envisaging a shared pathway-based approach may be the modulation of IP3-induced calcium release-a signaling pathway defective in a wide range of both recessive and dominant ataxias, including ITPR1, RNF168, SCA1, SCA2, and SCA3 (Shimobayashi and Kapfhammer, 2018) . The number of known ARCA genes has reached almost 200, with numbers still continuously growing. Recessive genes present with ataxia as a frequent or predominant feature (blue line) or as a non-obligatory but recurrent feature (distinction according to Rossi et al., 2018) .
The approach proposed here can prioritize research on molecular mechanisms and pathways shared not only across several ARCAs, but also across many neurodegenerative diseases. There is substantial clinical and pathogenetic overlap between ARCAs and other diseases, which are clinically classified as, e.g., HSP, myoclonus syndrome, leukodystrophy, or neurodegeneration with brain iron accumulation (NBIA) (Rossi et al., 2018; Synofzik and Sch€ ule, 2017) . While manifesting with (partly) different phenotypes, several of these conditions converge on common pathway hubs such as disturbed sphingolipid processing in several ARCAs, HSPs and leukodystrophies or impaired mitochondrial protease functioning in several ARCAs and HSPs (Rossi et al., 2018; Synofzik and Sch€ ule, 2017) . Classical divisive phenotype-driven classifications into ARCA, HSP, leukodystrophy, etc. thus need to be overcome by more molecular and pathway-oriented approaches, which might be amendable to common therapeutic approaches (Synofzik and Sch€ ule, 2017) .
With this vision on the horizon, it is important to keep in mind that each genetically defined ARCA has a unique pathophysiological mechanism that is not yet fully uncovered. Moreover, each molecular theme is not monolithic in itself but, in fact, entails many molecular mechanisms with various pleiotropic effects.
Disease Mechanism and Modeling
Some first exemplary clusters of shared molecular themes that might become of particular importance for translational approaches in ARCAs are: d Mitochondrial metabolism d DNA repair/genome stability d Complex lipid metabolism protein involved in different iron-dependent mitochondrial pathways. Phylogenetic, genetic, and biochemical studies point to the essential role of frataxin in iron-sulfur (Fe-S) cluster metabolism (reviewed in Martelli and Puccio, 2014) . Early studies performed on biological material from FA patients revealed (1) the presence of iron deposits in cardiomyocytes (Lamarche et al., 1980) , (2) decreased Fe-S cluster containing enzyme activities in heart homogenates (Rö tig et al., 1997), and (3) the presence of markers of oxidative damage in urine and blood (Schulz et al., 2000) . These three biochemical features are tightly interconnected and have been alternately proposed in the literature to be the primary event in the disease, leading to the hypothesis that frataxin deficiency results in a vicious circle with faulty iron handling, impaired Fe-S cluster synthesis, and increased oxygen radical production (Bayot et al., 2011) . From in-depth studies of different FA models, as well as intensive in vitro biochemical Review work, it is now widely accepted that the primary event following frataxin deficiency is the loss of Fe-S cluster biogenesis, given that frataxin acts as an allosteric regulator of the early part of Fe-S cluster biogenesis (Colin et al., 2013) . Fe-S clusters are essential inorganic protein cofactors implicated in key cellular functions ranging from mitochondrial respiration, iron metabolism, and translation to DNA repair ( Figure 3A ) (Martelli and Puccio, 2014) . Correspondingly, the lack of Fe-S cluster biogenesis caused by frataxin deficiency leads to mitochondrial dysfunction and iron dysmetabolism. Interestingly, frataxin inactivation triggered iron-accumulation-induced sphingolipid synthesis and the activation of the PDK1/Mef2 pathway, and this lead to aberrant transcription of target genes resulting in neurodegeneration (Chen et al., 2016a) . Sphingolipids and PDK1 activity were also found to be increased in heart samples from FA patients (Chen et al., 2016b) , suggesting that this pathway may contribute to pathology. However, recent data from a novel inducible frataxin knockdown mouse model suggest that the Pdk1/Mef2 pathway is not consistently activated (Chandran et al., 2017) .
Evidence suggests that oxidative stress may play a central role in FA pathophysiology (Tamarit et al., 2016) . It was suggested that the hypersensitivity to oxidative damage observed in models and FA patients could be due to deficient antioxidant defenses, in particular with the inability to activate the NRF2 pathway (Paupe et al., 2009 ). Furthermore, mTOR (target of rapamycin) is an important sensor of cellular energy state and a major hub for integration of environmental cues. As many of the processes governed by mTOR are dependent on iron, it is not surprising to find a close link between mTOR and Fe-S cluster biogenesis (La et al., 2013) . Interestingly, several components of the TORC1 signaling pathway are dysregulated in a Drosophila model of FA, and chemical inhibition of TORC1 by rapamycin treatment successfully restored the motor performance of the flies to normal levels (Calap-Quintana et al., 2015) . Similar results were obtained in cellular and mouse models of FA (Santoro et al., 2018) . Overall, these results suggest an interplay between mTOR and NRF2 pathways that could play part in the response to oxidative stress in the event of FA.
Considering the pleiotropic functions of Fe-S proteins, it is becoming clear that frataxin deficiency leads to multiple pathways deregulation, including mitochondrial metabolism, iron metabolism, DNA metabolism, and lipid metabolism. Further investigations are needed to identify the relative contribution of each pathway to the molecular pathogenesis of the disease. Impaired mitochondrial protein processing is a common hub in ARCA pathogenesis with some overlap to FA pathophysiology. SPG7 results from loss of function of the mitochondrial protein paraplegin, a conserved subunit of the ubiquitous m-AAA protease at the inner mitochondrial membrane. Paraplegin assembles with AFG3L2 (where dominant mutations cause spinocerebellar ataxia type 28 [SCA28] and recessive mutations cause autosomal-recessive spastic ataxia type 5 [SPAX5]) into hetero-oligomeric proteolytic complexes (Patron et al., 2018) (Figure 3B ). This m-AAA metalloprotease complex exerts pleiotropic tasks crucial for mitochondrial function, including mitochondrial proteome quality control (Patron et al., 2018) . Mutated m-AAA protease in SPG7 thus impairs mitochondrial protein control, leading to multiple secondary mitochondrial and extra-mitochondrial defects, such as respiratory deficiencies, morphological mitochondrial abnormalities, and defective axonal transport with subsequent axonal degeneration (Ferreirinha et al., 2004; Patron et al., 2018) . Interestingly, m-AAA proteases also regulate the assembly of the mitochondrial calcium uniporter (MCU) complex. Deregulated MCU complexes in AFG3L2-deficient mitochondria are associated with increased mitochondrial calcium uptake and increased vulnerability of neurons for calcium-induced cell death (Patron et al., 2018) . Correspondingly, a reduction of calcium influx into the cytosol of Purkinje cells rescued ataxia in an AFG3L2-deficient mouse model (Maltecca et al., 2015) , thus indicating a potential target for therapy. Recessive mutations in PITRM1, a mitochondrial matrix enzyme that degrades short oligopeptides, have recently been suggested to be associated with childhood-onset ARCA ( Figure 3B ) . PITRM1 is also involved in processing frataxin, leading to reduced levels of mature frataxin in case of mutant PITRM1 , thus demonstrating a link to FA pathophysiology. Biallelic mutations in PMPCA and PMPCB cause neurodegeneration and cerebellar atrophy (Jobling et al., 2015; Vö gtle et al., 2018) . PMPCA and PMPCB form the mitochondrial processing pepti-dase (MPP), an enzyme responsible for the cleavage mitochondrial targeting peptide signal ( Figure 3B ). Mitochondria isolated from fibroblasts of patients with PMPCB mutations showed accumulation of the processing intermediate of frataxin. In S. cerevisiae, PMPCB variants resulted in severe growth and MPP processing defects, leading to the accumulation of mitochondrial precursor proteins and early impairment of the biogenesis of Fe-S clusters. Patients with PMPCB mutations had decreased activity in Fe-S cluster-containing respiratory chain complexes and dysfunction of mitochondrial and cytosolic Fe-S cluster-dependent enzymes, again pointing to substantial overlap with FA pathogenesis (Vö gtle et al., 2018) . Mutations in POLG, the nuclear-encoded catalytic subunit of the mtDNA polymerase (responsible for mtDNA replication and repair) ( Figure 5 ), can present as ARCA (Coutelier et al., 2018) . Mutations in POLG thus cause mtDNA depletion that results in premature mitochondrial dysfunction with increased oxidative stress and nuclear DNA damage, leading to translocation of the tumor suppressor protein p53 into the nucleus, activation of apoptosis, and repression of PGC-1a, the master regulator of mitochondrial biogenesis and cellular antioxidant response (Safdar et al., 2016) . As for FA, it is probable that, secondary to these primary dysfunctions, multiple pathways with differential cell vulnerability are involved in the complex pathogenesis, thus leading to heterogeneous phenotypic presentations (Synofzik et al., 2012) .
COQ8A-associated autosomal-recessive ataxia is due to mutations in COQ8A (formerly: ADCK3), which is involved in coenzyme Q (CoQ) biogenesis ( Figure 3B ) (Lagier-Tourenne et al., 2008) . COQ8A, a member of the UbiB atypical protein kinase-like family, is required for complex Q integrity and enhances CoQ biogenesis, although its precise biochemical function is not known (Stefely et al., 2016) . In vivo, loss of COQ8A in mouse and cell models leads to complex Q destabilization and a variable reduction of CoQ in some tissues (Stefely et al., 2016) . Mouse models do not show mitochondrial defects or increased oxidative stress but rather a defect in Golgi and endoplasmic reticulum (ER) in cerebellar Purkinje cells with no obvious CoQ deficit in the cerebellum (Stefely et al., 2016) . In contrast, fibroblast cell lines derived from COQ8A patients display signs of oxidative stress, defects in mitochondrial homeostasis, and an increase in lysosomal content (Cullen et al., 2016) . Thus, whether CoQ10 deficiency is central to COQ8A ataxia or whether other lipiddependent pathways are involved remains to be uncovered.
Mitochondrial function is at least secondarily impaired also in ARSACS. ARSACS is due to the loss of function of the sacsin protein. Several recent lines of evidence from patient cells, as well as from mouse models, suggest that sacsin acts as a chaperone or regulator for the organization of the intermediate filament cytoskeleton (Duncan et al., 2017) . Sacsin deficiency thus leads to an altered organization of these intermediate filaments and-probably downstream-alterations in multiple mitochondrial functions, including mitochondrial fission (Girard et al., 2012) , oxidative phosphorylation (Criscuolo et al., 2015) , and oxidative stress pathways (Duncan et al., 2017) . This might explain the partly ''mitochondrial clinical features'' observed in several ARSACS patients (such as, e.g., ophthalmoplegia, epilepsy, or hearing impairments). The process of Fe-S cluster assembly occurs within a complex consisting of NFS1-ISD11-ACP, the cysteine desulfurase providing the sulfur, ISCU, and eventually frataxin (FXN), which regulates the NFS1 activity and the entry of iron within the complex (Colin et al., 2013) . Once assembled, the cluster on ISCU is transferred to acceptor proteins with the help of additional proteins. Alternatively, a still uncharacterized compound provided by the mitochondrial machinery is exported to the cytosol via ABCB7 and is used by the cytosolic Fe-S cluster assembly machinery to assemble Fe-S clusters for cytosolic and nuclear acceptor proteins. Fe-S cluster proteins (in orange) are found in numerous essential cellular processes, including oxidative phosphorylation (respiratory chain complexes I, II, and III), Krebs cycle (aconitase, ACO2), heme biosynthesis (ferrochelatase), iron metabolism (IRP1/c-ACO), protein translation (ABCE1) and ribosome assembly, amino acid metabolism and tRNA modification, DNA metabolism, and telomere length control. (B) Schematic representation of the mitochondrial protein processing hub affected in ARCAs. The m-AAA protease, a hetero-oligomeric complex composed of paraplegin and AFG3L2, degrades defective proteins to help maintain the respiratory chain. Peptides can be further degraded into amino acids by PITMR1. Nuclear-encoded mitochondrial proteins are imported through the TOM/TIM complex and are further matured. The mitochondrial processing peptidase (PMPCA/PMPCB) is involved in cleaving the mitochondrial targeting sequence (MTS). Proteins involved in ARCA are in red.
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Neuron Review 2.2. Impaired DNA Repair DNA repair pathways are impaired in several ARCAs, affecting different DNA repair mechanisms, including single-and double-strand break (DSB) repair and base excision repair (Table 2) . ATM, the protein deficient in ataxia telangiectasia (AT), is regarded as the primary transducer of the DSB alarm (Shiloh, 2003) . On binding to sites of DNA damage, the ATM dimer dissociates to its active monomer. ATM is a serine/threonine protein kinase of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family that responds swiftly to DSB by phosphorylation of numerous substrates, including the histone H2AX, which plays an important role in genome packaging and chromatin restructuring at damaged DNA sites ( Figure 4A ) (Fernandez-Capetillo et al., 2004) . Other important substrates of ATM are the protein kinase Chk2 and the transcription factor p53. Activated p53 regulates a variety of cellular processes such as transcription, cell cycle regulation, and apoptosis (Chang et al., 2012) . In general, ATM responds to several stress and growth signals to regulate DNA damage response of DSBs, cell growth, antioxidant defense, autophagy and mitophagy, protein synthesis, glucose metabolism, and neurotransmitter release (Choy and Watters, 2018) . These multiple cellular pathways regulated by ATM are reflected clinically by the multisystemic features including degeneration of diverse neuronal systems (cerebellar, cortical, peripheral), increased sensitivity to ionizing radiation, cancer, immune deficiency, and diabetes.
MRE11 is part of the Mre11-Rad50-Nbs1 complex (MRNcomplex) that recruits ATM to the site of DSBs in nuclear DNA. Mutations in MRE11 result in ataxia-telangiectasia-like disorder (ATLD) (Taylor et al., 2004) . Mutations in SETX cause oculomotor apraxia type 2 (AOA2), another ARCA caused by impaired DSB repair. The corresponding protein, senataxin, resolves RNA:DNA hybrids forming at DNA DSB to prevent translocations. Hereunto, it is recruited at DSBs when they occur in transcriptionally active loci ( Figure 4A ) (Cohen et al., 2018) . The xeroderma pigmentosa and Cockayne syndrome proteins XPA, ERCC4/XPF, ERCC5/XPG, ERCC6/CSB, and ERCC8/CSA are key enzymes Here, the inactive ATM dimer dissociates into active monomers that phosphorylate multiple proteins, including H2Ax, to promote chromatin relaxation. In addition, poly(ADP-ribose) polymerase 1 (PARP1) recognizes the strand break and attaches ADP-ribose units from NAD + to many nuclear binding proteins. Several chromatin remodeling and DNA damage proteins bind to poly(ADP-ribose) in DNA damage foci and support DNA repair (Guleria and Chandna, 2016) . Senataxin (SETX) resolves RNA from RNA:DNA hybrids built in the vicinity of the break (Cohen et al., 2018) . (B) Single-strand breaks (SSBs) are detected by PARP1. PNKP catalyzes the phosphorylation of 5 0 -OH termini and the dephosphorylation of 3 0 -phosphate termini resulting from ROS-mediated sugar damage. Abortive TOP1 reactions are processed by TDP1. APTX is required for the processing of 5 0 AMP-associated SSBs. GAP filling in mitochondria is mediated by polymerase gamma (POLG) and nicks are sealed by ligase 3 in interactions with XRCC1. In long-patch SSBs, overhanging flaps of DNA are displaced synergistically by the flap structure-specific endonuclease, FEN1, and the DNA replication helicase 2 (DNA2). ARCA genes are indicated in red. of nucleotide excision repair constituting another group of ARCAs due to impaired DNA repair, reviewed recently (Khobta and Epe, 2013; Koch et al., 2016) (Table 2 ).
In addition, at least four ARCA genes are involved in singlestrand break repair (Table 2 ). APTX (aprataxin; causing ataxia with oculomotor apraxia type 1, AOA1), PNKP (polynucleotide kinase/phosphatase; causing ataxia with oculomotor apraxia type 4, AOA4), and TDP1 (tyrosyl DNA phosphodiesterase 1; causing autosomal recessive spinocerebellar ataxia with axonal neuropathy, SCAN1) are jointly involved in DNA end processing in single-strand repair, exploiting XRCC1 (X-ray-repair crosscomplementing protein-1) as an important scaffold protein for DNA repair ( Figure 4B ). XRCC1 mutations, as well as other defects of DNA-strand-break repair, result in hyperactivation of poly(ADP-ribose) polymerase 1 (PARP) coded by the PARP1 gene (Hoch et al., 2017) . PARP attaches ADP-ribose units from NAD+ to DNA binding proteins like core histones to support the process of repair. PARP hyperactivation results in a depletion of NAD + , causing disruption of cellular energetics (Fang et al., 2014) .
This demonstrates that defects in DNA repair mechanisms are a common molecular hub underlying ARCAs. In at least some of these DNA repair genes, a common pathogenic mechanism might be their role in maintenance of not only nuclear but also mitochondrial DNA and function. As the mitochondrial genome does not encode DNA repair proteins, mitochondria completely depend on nuclear factors for the replication and repair of its DNA. In addition, mitochondria produce substantial amounts of reactive oxygen species (ROS) by oxidative phosphorylation in the mitochondrial matrix where mtDNA is exposed to heavy loads of oxidative damage (Sykora et al., 2012) . Of interest, aprataxin, TDP1, MRE11, and PNKP are four ARCA proteins involved in DNA repair that have all been shown recently to be present in mitochondria, as well as in the nucleus, and to be essential for mtDNA homeostasis (Das et al., 2010; Sykora et al., 2011; Tahbaz et al., 2012) (Figure 5) .
The same seems to be valid for ATM. Although it shows a nuclear localization in dividing SHSY5Y cells and is mainly cytoplasmic in postmitotic neurons, it has more recently also been localized to mitochondria (Valentin-Vega et al., 2012) . AT fibroblasts have low levels of ribonucleotide reductase (the rate-limiting enzyme in the synthesis of deoxyribonucleotide triphosphates) and reduced mtDNA copy numbers (Eaton et al., 2007) . AT cells also show diminished levels of DNA ligase 3, the only known DNA ligase functioning in the mitochondria (Sharma et al., 2014) . Furthermore, cytochrome c oxidase Figure 5 . Central Role of Mitochondria in ARCAs with Impaired DNA Repair (A, pink) Lack of ATM, a key protein in double-strand break repair of nuclear DNA, leads to increased levels of the poly(ADP-ribose) polymerase (PARP1) as do mutations in ERCC6/CSAB, ERCC8/CSA, and XPA that are mainly involved in nucleotide excision repair. Overload of PAPRP1 causes an increase in the mitochondrial membrane potential and consecutively triggers cleavage of PINK1. Lack of PINK1 results in enlarged mitochondria and increased reactive oxygen species (ROS) causing neurodegeneration (Fang et al., 2014) . (B, blue) In mitochondria, ROS is damaging mtDNA mainly by causing single-strand breaks (SSBs). TDP1, APTX, and PNKP are coding for key proteins in SSB repair of mtDNA. Mutations in these genes result in defective mtDNA with negative effects on respiratory chain complexes and mitochondrial function as do mutations in ERCC6/CSAB and ERCC8/CSA responsible for base excision repair. (C, yellow) Similarly, mutations in the single mtDNA polymerase gamma (POLG) and the mtDNA helicase (Twinkle/TWNK) lead to impaired replication of the mtDNA, with mtDNA depletion and impaired respiratory chain function resulting in degeneration especially of huge neurons with highly energy demand like, e.g., Purkinje cells and dorsal root ganglia affected predominantly by mutations in DNA repair genes. activity (complex IV) was found to be significantly diminished in ATM-deficient mice (Patel et al., 2011) . Additionally, deficiency of ATM (but also of ERCC6/CSB and XPA) results in increased ROS production, hyperpolarization of the mitochondrial membrane, mitochondrial fusion, and defective mitophagy, resulting in impaired clearance of damaged mitochondria (Fang et al., 2014) . All these findings suggest ATM to be of major importance for the maintenance of mitochondrial function (Choy and Watters, 2018) .
Interestingly, many Fe-S proteins are involved in nuclear/ mitochondrial DNA repair or DNA metabolism (NTHL1, ERCC2/ XPD, DNA2, POLD1, PRIM2) (Fuss et al., 2015) . This also links FA to DNA damage repair. Indeed, increased nuclear DNA damage has been measured in peripheral blood cells from FA individuals (Haugen et al., 2010) , and reduced capacity of DNA damage repair is evident in multiple models of FA (Shen et al., 2016) . Furthermore, increased mtDNA damage has also been recently identified in FA fibroblasts (Bhalla et al., 2016) , suggesting that increased burden of nuclear and mitochondrial DNA damage could also contribute to the FA disease mechanism.
A still unsolved question is how deficits in different DNA repair mechanisms cause the predominant damage of neuronal cells, especially in the cerebellum. It has been speculated that the enormous size of Purkinje cells, sensory neurons in dorsal root ganglia, and lower motor neurons in the spinal cord require high levels of oxidative metabolism and subsequent ROS generation, causing mtDNA damage that makes them especially vulnerable to DNA repair deficits (Gilmore, 2014) ( Figure 5 ).
Lipid Metabolism in ARCAs
Traditionally, genetic disorders related to defects in lipid metabolism (including ARCAs) have been classified according to organelles like lysosomes, peroxisomes, or the ER. With the development of NGS, it becomes difficult to classify the increasing number of newly discovered diseases affecting lipids in which many intracellular organelles are involved. Accordingly, the classification has been refined based on metabolic pathways and lipid classes (Lamari et al., 2015) . ARCAs have been linked to disturbances in fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol, or prenol lipids, sometimes also affecting several of these lipid classes. These ARCAs will be addressed here, with particular emphasis on treatable conditions. Sterol lipids. A recurrent sterol lipid ARCA is Niemann-Pick type C (NPC), accounting for about 1%-2% of all ARCAs (Synofzik et al., 2015) . NPC primarily affects the trafficking of intracellular cholesterol in the brain and peripheral organs. The disease is due to mutations in the NPC1 (95%) or NPC2 (5%) genes. NPC1 encodes a large transmembrane protein projecting into the lumen of endosomes or lysosomes. By contrast, NPC2 encodes a small soluble glycoprotein present in lysosomes and various secreted fluids. NPC1/2 deficiency results in altered processing and utilization of endocytosed cholesterol, which leads to the storage of unesterified cholesterol and secondary alterations of sphingolipid metabolism, especially increased GM2 and GM3 gangliosides in cerebral gray matter. As the disease progresses, neuronal death affects predominantly Purkinje cells of the cerebellum (Walkley and Suzuki, 2004) . In NPC, plasma oxysterols (cholestane-3b,5a,6b-triol), sphingolipids (lysosphingomyelin-509), and bile acids (3b,5a,6b-trihydroxy-cholanoyl-glycine) can be used as first-line diagnostic biomarkers. These biomarkers, as well as the filipin staining test (which demonstrates impaired trafficking of endocytosed cholesterol in living fibroblasts), can also be of critical diagnostic help in patients for whom genetic testing did not identify two pathogenic mutations or for functional validation of NPC1/2 variants of uncertain significance.
A rarer but likewise treatable sterol lipid ARCA is cerebrotendinous xanthomatosis (CTX). CTX is caused by biallelic mutations in CYP27A1 encoding the mitochondrial cytochrome P-450 enzyme sterol 27-hydroxylase. This defect interferes with the initial side-chain oxidation step of the sterol intermediates in the alternative bile acid pathway. This results in reduced synthesis of 27-hydroxycholesterol (27-OHC) and chenodeoxycholic acid (CDCA), as well as shunt of sterol intermediates into the microsomal pathway for cholic acid formation (Salen et al., 1991) . CTX is also associated with high production of cholestanol, which accumulates in different tissues, and increased levels of bile alcohols in urine (Berginer et al., 1984) . Evidence that cholestanol may be neurotoxic is supported by the finding of cholestanol deposition and apoptosis in neurons of rats fed a 1% cholestanol diet (Inoue et al., 1999) . CTX is easily diagnosed by measuring plasma cholestanol. 27-OHC is substantially decreased, and as the flux of 27-OHC may be involved in brain cholesterol homeostasis, the lack of 27-OHC may affect cholesterol synthesis in the brain.
Glycerophospholipids. As important as the biosynthesis of glycerophospholipids is the continuous remodeling of their structure through phospholipases and acyltransferases. Two of them have been associated with ARCA: patatin-like phospholipase domain-containing protein 6 (PNPLA6) and phospholipase A2 group VI (PLA2G6) (Tesson et al., 2012 ) (see Figure 6 ). PNPLA6 de-esterifies phosphatidylcholine into its constituent fatty acids and glycerophosphocholine, which serves as a precursor for the biosynthesis of acetylcholine. PLA2G6 catalyzes the deacylation of phosphatidylcholine with release of unsaturated fatty acid chains such as arachidonic acid, which is the starting molecule of many complex fatty acids, like prostaglandins and leukotrienes. Notably, PLA2G6 knockout mice present with cerebellar atrophy due to loss of Purkinje cells and glial cell activation (Zhao et al., 2011) .
Sphingolipids. ARCAs have been associated with enzymatic defects altering both biosynthesis and catabolism of sphingolipids. Such enzyme deficiencies can be measured in skin fibroblasts or leukocytes and the diagnosis confirmed by molecular analyses. Arylsulfatase A (ARSA) initiates the degradation of sulfatides and produces galactosylceramide. Galactosylceramide and sulfatides are major glycosphingolipids in the myelin sheath. ARSA deficiency causes metachromatic leukodystrophy (MLD), which is characterized by sulfatide accumulation and decreased galactosylceramide, both contributing to myelin pathology. The excess in sulfatides may also trigger microglial activation (Jeon et al., 2008) . ARSA-deficient mice display significant loss of Purkinje cells but, unlike in human disease, no cerebral demyelination (Matzner et al., 2005) . Sulfatiduria is a diagnostic urine biomarker of MLD. Deficiency of galactosylceramidase, encoded by GALC, can present with predominant cerebellar ataxia in late onset forms of Krabbe disease (Shao et al., 2016) . Unlike MLD, patients with Krabbe disease present increased concentrations of galactosylceramide, which is toxic for oligodendrocyte differentiation and survival (Won et al., 2013) .
Glucosylceramide is involved in ARCA through three different diseases. The lysosomal glucocerebrosidase (GBA1) hydrolyzes glucosylceramide into ceramide. GBA1 deficiency leads to the buildup of glucosylceramide, with biallelic mutations causing Gaucher disease and heterozygous mutations presenting a genetic risk factor for Parkinson's disease. GBA1 reaches the lysosome via lysosomal integral membrane protein type 2 (LIMP-2), which is encoded by SCARB2. SCARB2 mutations lead to decreased GBA activity with subsequent glucosylceramide accumulation and are associated with renal pathology, progressive myoclonus epilepsy, and ataxia (Reczek et al., 2007) . More recently, mutations in GBA2 were identified in ARCA patients presenting with additional spasticity and/or cataracts (Martin et al., 2013) . Unlike GBA1, GBA2 is mostly expressed in the ER and may constitute an alternative pathway to produce ceramide outside the lysosome (Astudillo et al., 2015) .
Abnormal GM2 ganglioside metabolism has been identified in two ARCAs. Deficiency in hexosaminidase A (HEXA), also called GM2 gangliosidosis or Tay-Sachs disease, leads to the accumulation of GM2 gangliosides. Conversely, B4GALNT1 encodes b-1,4-N-acetylgalactosaminyltransferase 1, which synthesizes both GM2 and GD2 gangliosides in the Golgi apparatus. Its deficiency causes a lack of GM2 gangliosides and an excess of GM3 gangliosides (Harlalka et al., 2013) .
Fatty Acyls and Prenol Lipids. ARCAs involving fatty acyls (e.g., very long-chain fatty acids [VLCFAs]) and prenol lipids (e.g., phytanic and pristanic acids) are mostly related to peroxisome metabolism (De Munter et al., 2015) . Refsum disease is caused by impaired a-oxidation of phytanic acid, due to either a deficiency in phytanoyl-CoA hydroxylase (PHYH) or PEX7 mutations that affect the import of PHYH into the peroxisome. The resulting accumulation of phytanic acid serves as a biomarker of Refsum disease and is thought to induce oxidative damage and mitochondrial dysfunction. PHYH knockout mice fed a diet supplemented with phytol, the precursor of phytanic acid, exhibited loss of Purkinje cells and peripheral neuropathy (Fernandez-Capetillo et al., 2004) .
ARCA can be related to deficient D-bifunctional protein (DBP), encoded by the HSD17B4 gene, which catalyzes the oxidation of VLCFA, pristanic acid, and bile acid intermediates. Due to the residual DBP enzyme activity, plasma levels of VLCFA and pristanic acid may, however, be normal. Defects in peroxisome biogenesis, which requires the concerted action of at least 14 peroxins encoded by distinct PEX genes, can also cause ARCA. Metabolically, these patients share mildly increased 
Steps to Clinical Translation
Evolution of new therapies in ARCA requires a close interplay of basic and clinical research as outlined in Figure 7 . For preparing translational studies targeting rare diseases like ARCA, creation of representative registry-inventoried cohorts of genetically stratified patients is critical, allowing to delineate phenotypic subgroups and the natural history for each ARCA. Such cohorts have been built up for Friedreich's ataxia (European Friedrich's ataxia consortium for translational studies [EFACTS]; Reetz et al., 2015) and on a national and age-dependent level for AT (Jackson et al., 2016) . The consortium PREPARE (PREParing therapies for Autosomal REcessive ataxias) is currently preparing trial-ready cohorts, focusing on ARSACS and COQ8A, with SPG7 and other ARCAs under way (https://www.prepareataxia.com/). At present, a major shortcoming for interventional trials in most ARCAs is the lack of data on disease progression. Whereas clinical rating scales, like the Scale for the Assessment and Rating of Ataxia (SARA; scoring from 0 to 40 points, with higher scores indicating more severe disease; Schmitz-H€ ubsch et al., 2006) , have been established as valid measures of disease severity more than a decade ago, prospective quantitative data on the natural disease progression that allow for the calculation of the number of patients needed to treat are available only for FA (Reetz et al., 2016) and ARSACS (Gagnon et al., 2018) . As the progression of ataxia is slow in most ARCAs (e.g., increase by 0.8 SARA points/year in FA and 1.3 SARA points/years in ARSACS), clinical differences will be unraveled in therapeutic trials only after long-term interventions and in large groups of patients. As calculated recently for FA, even an effective intervention that has the potential to slow down disease progression by, e.g., 50% is likely to fail in a controlled trial of 1 or 2 years duration if >400 patients are not available (Reetz et al., 2016) . To overcome this problem, objective, less variable measures that reflect disease activity and depict disease progression are highly desirable as clinical trial outcome parameters. Regional brain atrophy on MRI has been shown to be more sensitive than clinical scores in the detection of disease progression in dominantly inherited ataxias (Adanyeguh et al., 2018) . In ARCAs, imaging progression markers are scarce but are evolving for FA (Dogan et al., 2018) , as well as for ARSACS and COQ8A, in the ongoing longitudinal studies by PREPARE. Neurophysiological parameters, such as saccade velocity, have been used successfully as a surrogate marker in a trial with miglustat in NPC and were the key marker that facilitated European Medicines Agency (EMA) approval for treatment in NPC (Patterson et al., 2007) . Fluid biomarkers may serve to the same end and can be differentiated into two classes: (1) generic biomarkers of neurodegeneration that are not specific to the disease process but still allow the capture of the neuronal damage. For example, neurofilament light chain (NfL) reflects neuronal turnover in many neurodegenerative diseases, including first-promise studies in cerebellar ataxias, and can be accessed in blood with close correlation to CSF levels (Wilke et al., 2018) . (2) Disease-specific markers that are closely related to pathophysiology and reflect early steps in pathogenesis may capture the direct target engagement of a compound and its efficacy. For some ARCAs, the disease protein itself may constitute such a disease-specific biomarker as most ARCA subtypes derive from loss-of-function mutations, e.g., frataxin in FA. Indeed, frataxin levels have already been used as the primary outcome measure in preclinical and clinical studies in FA (Libri et al., 2014; Soragni et al., 2014) . In ARCA related to lipid metabolism, the abnormal accumulating metabolite can be a disease-specific biomarker reflecting treatment response, such as plasma cholestanol concentrations in CTX or phytanic acid in Refsum disease.
Inclusion criteria
• Gene c • Clinical However, such biomarkers require thorough validation for correlation with disease severity and response to treatment in the relevant tissue. For example, in MLD, ARSA activity reaches normal levels in blood shortly after hematopoietic stem cell transplantation. However, ARSA does not cross the blood-brain barrier. This likely explains why the disease remains progressive after transplantation in most patients despite normalization of ARSA levels in blood and a close correlation of disease severity with residual ARSA activity in the natural course of MLD (Boucher et al., 2015; Groeschel et al., 2016) .
Interventional trial

Treatment Strategies in ARCA 4.1. Modification of Disease Pathways
Various therapeutic approaches have been applied in ARCAs where the corresponding-often metabolic-defect has been identified. These treatments involve (1) supplementation of compounds with impaired synthesis or import, (2) reduction of toxic metabolites, and (3) modification of pathogenic downstream effects (Table 4) .
4.1.1. Supplementary therapies. AVED is caused by mutations in the tocopherol a transfer protein gene (TTPA). When mutated, TTPA prevents vitamin E from passing into general circulation. High-dose oral tocopherol a can stop or even reverse disease progression. Initiation of treatment in the presymptomatic phase can prevent the development of symptoms (El Euch-Fayache et al., 2014) . Similarly, abetalipoproteinemia is due to altered assembly and secretion of apolipoprotein B-containing lipoprotein particles due to mutations in MTP encoding the microsomal triglyceride transfer protein. This results in hypocholesterolemia and malabsorption of lipid-soluble vitamins, i.e., vitamins A, D, E, and K. Treatment consists of a low-fat diet with oral supplementation of high-dose tocopherol a, high dose b carotene, 25-hydroxy-vitamin D3, and vitamin K.
Vitamin B is another important group of vitamins to consider in ARCA, especially thiamine (B1), riboflavin (B2), and biotin (B8). Biotin is required for multiple biotin-dependent metabolic processes. Biotinidase recycles free, non-protein-bound biotin. Its deficiency can present as ARCA that responds very well to long-term biotin supplementation (Wolf, 2017) . Biotin-thiamineresponsive basal ganglia disease is caused by mutations in SLC19A3 encoding human thiamine transporter 2. Patients usually manifest with subacute encephalopathy associated with cerebellar ataxia and dystonia, often associated with typical MRI features (Debs et al., 2010) . High oral dose of biotin, associated with thiamine, allows symptoms to resolve within days and usually prevents the reoccurrence of metabolic crises. Recently, another form of ARCA associated with optic atrophy, sensorineuronal deafness, and peripheral neuropathy has been linked to mutations in SLC52A2 encoding a riboflavin transporter involved in Brown-Vialetto-Van Laere syndrome, which is responsive to riboflavin supplementation (Guissart et al., 2016) .
In ARCA, due to COQ8A mutations, the synthesis of coenzyme Q10 itself is deficient. Supplementation by coenzyme Q10 seems to improve motor dysfunction in some COQ8A-mutated patients, but results are rather variable (Mignot et al., 2013) . These mixed results might be explained by the possible heterogeneity of the involved pathways, which extend beyond mere CoQ10 deficiency in several tissues.
Reduction of Toxic Metabolites.
In CTX, chenodeoxycholic acid (CDCA) remains the treatment of choice as it downregulates CYP7A, restores the imbalance between CDCA and cholic acid, and is the only drug that has shown effectiveness on neurological symptoms so far (Nie et al., 2014) . The exogenous supply of CDCA acts by attenuating a negative feedback in the endogenous bile acid and cholestanol synthesis. This drastically lowered plasma cholestanol concentrations in patients and its accumulation in tissues (Berginer et al., 1984; Nie et al., 2014) . Long-term clinical benefit was demonstrated in most patients with CTX (Berginer et al., 1984) provided that treatment was initiated less than 15 years after the onset of neurological symptoms (Yahalom et al., 2013) . In Refsum disease, a significant lowering of phytanic acid concentrations can be obtained by reducing dietary intake of phytanic acid while ensuring sufficient caloric intake to avoid mobilization of stored lipids, including phytanic acid, into the plasma. Long-term benefit of dietary intervention was shown on phytanic acid levels (Baldwin et al., 2010) . However, this may be not sufficient in some patients to prevent acute attacks and stabilize the progressive course. Lipid apheresis can then be a complementary or an alternative therapeutic strategy to lower phytanic acid concentrations (Zolotov et al., 2012) . Reduction in plasma phytanic acid concentration is usually accompanied by improved ichthyosis, sensory neuropathy, and ataxia. Therapeutic strategies for NPC include pharmacologic inhibition of substrate accumulation. Miglustat is a substrate reduction therapy that aims at lowering glycolipid storage. It inhibits glucosylceramide synthase and stabilizes disease progression in adolescent and adult patients (Patterson et al., 2007; Wraith et al., 2010) but is not yet approved for NPC by the FDA. Frequent adverse events are diarrhea, tremor, and weight loss. Cyclodextrins are thought to replace the function of NPC1/2 within the late endosome/lysosome compartment. Administration in mouse and cat models of NPC reduced unesterified cholesterol and glycolipid accumulation within the brain and peripheral organs. In an open-label trial, 14 patients with NPC received increasing doses of 2-hydroxypropylb-cyclodextrin intrathecally and showed slower disease progression compared to a historical cohort of 21 patients (Ory et al., 2017) . A phase 2/3 trial is ongoing (NCT02534844). However, 2-hydroxypropyl-b-cyclodextrin is ototoxic so that safer alternative cyclodextrins should be considered (Davidson et al., 2016) . Miglustat was also used in neuronopathic Gaucher disease to decrease glucosylceramide concentrations but failed to show efficacy. Novel substrate reduction therapies are being developed with more targeted actions on the central nervous system and therefore fewer side effects. Although a rare cause of ARCA, the pathophysiology of Wilson disease is closely related to copper toxicity. First-line treatments are copperchelating agents such as D-penicillamine, trientine, and/or zinc (Ala et al., 2007) .
4.1.3. Modification of Downstream Events. In FA, a number of drugs targeting downstream events of frataxin deficiency are at various stages of development, with many already in clinical trials (for a full updated review, see FARA Pipeline, http://www. curefa.org/pipeline). These include improving mitochondrial function and energy metabolism, antioxidant strategies, and iron chelator approaches. One compound that has been Lack of bile acids (e.g., CDCA) and accumulation of abnormal lipids (e.g., cholestenol)
Oral supplementation of chenodeoxycholic acid (CDCA) Berginer et al., 1984; Nie et al., 2014 Refsum disease (PHYH, PEX7) Accumulation of phytanic acid Dietary restriction of phytanic acid, lipid apheresis Baldwin et al., 2010; Zolotov et al., 2012 Niemann-Pick type C/NPC (NPC1, NPC2) Glycolipid storage, accumulation of unesterified cholesterol Miglustat, Cyclodextrin Ory et al., 2017; Patterson et al., 2007 Wilson disease (ATP7B) Accumulation of copper in liver and brain D-penicillamine, trientine, and/or zinc Aggarwal and Bhatt, 2018 Chaperone and replacement therapies Gaucher disease type 3 (GBA) Lack of glucocerebrosidase Ambroxol Narita et al., 2016 Metachromatic leukodystrophy/MLD (ARSA)
Lack of arylsulfatase A Intrathecal enzyme replacement therapy, hematopoetic stem cell transplantation Groeschel et al., 2016 Krabbe disease (GALC) Lack of galactosylceramidase Hematopoetic stem cell transplantation Laule et al., 2018 
Modifiers of gene expression
Friedreich's ataxia/FA (FXN) Lack of frataxin HDCA inhibitors (109/RG833, nicotinamide) to reverse epigenetic gene silencing Herman et al., 2006; Libri et al., 2014; Soragni and Gottesfeld, 2016 Ataxia telangiectasia/AT (ATM) Lack of ATM protein Glucocorticoid induction of non-canonic splicing events in mutant ATM mRNA precursor leading to novel ATM transcripts Menotta et al., 2017 Nucleic acids influencing specific gene expression drost et al., 2011; Lynch et al., 2010; Meier et al., 2012) . While modulation of mitochondrial function and attenuation of oxidative load is logical and might provide some future therapeutic option, the use of iron chelators such as deferiprone should be tested with caution as recent evidence demonstrated that depletion of mitochondrial iron further exacerbate the phenotype (Martelli et al., 2015; Pandolfo et al., 2014) .
Restoration of Disease Proteins
Many ARCAs are caused by the lack of functional disease protein. This may be restored by (1) regeneration of misfolded proteins via chaperons, (2) slowing down the protein degradation process, or (3) direct replacement of the respective protein.
Chaperone Therapy.
For ARCA related to enzymatic deficiencies, drugs have been developed that can increase residual enzymatic activity while reaching the central nervous system unlike most systemic enzyme replacement therapies. In contrast to the large size of enzymes, pharmacological chaperones are small molecules ready to cross the blood-brain barrier and correct the folding of misfolded proteins, allowing them to pass through the cell's quality-control system. Most of them are still under development in ARCA. Nonetheless, ambroxol, a commercially available expectorant, was shown to enhance glucocerebrosidase activity in mouse brain possibly via a chaperone mechanism. A pilot open-label study was conducted in five patients with neuronopathic Gaucher disease: high-dose oral ambroxol increased glucocerebrosidase activity decreased CSF glucosylceramide concentrations and showed some clinical benefit (Narita et al., 2016) . In GM2 gangliosidosis, a small-molecule library screening identified pyrimethamine as a possible mutation-specific pharmacological chaperone (Maegawa et al., 2007) . However, pilot clinical trials were disappointing (Clarke et al., 2011) as overt side effects occurred promptly when doses increased. 4.2.2. Protein Stabilization. Erythropoietin (EPO), a hormone that stimulates erythropoiesis, has been shown to increase fra-taxin levels in peripheral blood mononuclear cells (PBMCs) of FA patients (Sturm et al., 2005) . This increase is thought to occur at the posttranscriptional level, since no FXN mRNA increase was observed (Acquaviva et al., 2008) . Six clinical trials have tested various forms of recombinant EPO in FA patients at various concentrations; however, all showed limited frataxin increase and failed to establish significant changes in cardiac and neurological clinical parameters (Boesch et al., 2014; Sturm et al., 2005) . Altogether, although well tolerated, these clinical trials demonstrate that EPO is not a useful disease-modifying therapy in FA.
Another approach to increase frataxin levels is to prevent its degradation. Frataxin is produced in the cytosol as a precursor with an N-terminal mitochondrial targeting signal. During mitochondrial import, the precursor undergoes a two-step catalytic processing to generate the mature functional form (Schmucker et al., 2008) . During the normal maturation process, a significant amount of frataxin precursor undergoes ubiquitin-mediated degradation through the ubiquitin-proteasome system (UPS) (Rufini et al., 2011) . Recent studies have demonstrated that preventing degradation of frataxin, thereby promoting accumulation of the mature form, could be obtained either by using ubiquitincompeting molecules that dock on the frataxin ubiquitination site or by inhibiting RNF126, the E3 ligase responsible for frataxin ubiquitination (Benini et al., 2017) . 4.2.3. Protein Replacement. Enzyme replacement is the most prominent example of a direct supplementation of the disease protein. In MLD, an intravenous application of arylsulfatase A failed to improve the course of disease, most likely, as the large protein failed to cross the blood-brain barrier. The results have not yet been released for an intrathecal enzyme replacement approach tested in a phase I/II doseescalation study.
In FA, a strategy for protein replacement has been developed using cell-penetrant peptides, such as transactivator of transcription (TAT) (Vyas et al., 2012) . TAT is a short, cationic peptide capable of efficiently delivering protein cargo into multiple tissues and organelles, including mitochondria. Treatment of the severe conditional NSE-Cre mouse model with deletion of frataxin in the heart and neural crest-derived tissues with TAT-FXN increases survival and partial rescue of cardiac function (Vyas et al., 2012) . The development of this strategy is ongoing, and CTI-1601 (TAT-FXN) has recently obtained orphan drug status (https://chondrialtherapeutics.com).
Gene-Related Therapy
As many ARCAs are caused by loss-of-function mutations, increasing gene expression is a promising approach in this disease group. Gene-related therapies for ARCAs have been developed furthest in FA: recent strategies to restore frataxin show a promising potential for slowing or stopping disease progression (Figure 8 ). Yet, several of the treatment principles applied here might well be applicable in analogy to other ARCAs as well in the future. Thus, while focusing on FA in the next sections, we present the gene-related approaches under a generic systematic perspective for ARCAs. 4.3.1. Regulation of Gene Expression. As 98% of FA mutations are intronic GAA expansions resulting in heterochromatin formation of the locus, leading to reduced expression of the FXN gene, FA is paradigmatic for disorders caused by reduced expression of a per se normal gene (Campuzano et al., 1996; Saveliev et al., 2003) . Histone deacetylase (HDAC) inhibitors reduce epigenetic silencing of genes by reverting chromatin to an open and active state for gene transcription. In preclinical studies, 2-aminobenzamide class I HDAC inhibitors were found to be the most effective to increase frataxin in patient-derived cell lines, including neuronal cells derived from patient iPSCs (induced pluripotent stem cells), and in GAA-based mouse models (Herman et al., 2006; Soragni and Gottesfeld, 2016) . This led to the development of compound 109/RG833 for a phase Ib clinical trial in 20 adults with FA. RG833 was found to increase frataxin mRNA in circulating lymphocytes by 1.5-fold and was well tolerated (Soragni and Gottesfeld, 2016) . However, as potential toxic metabolites were detected, additional compounds are currently being synthesized for further clinical development.
Nicotinamide (vitamin B3), a classical class III HDAC inhibitor with good bioavailability and good safety profile was found to upregulate frataxin in preclinical models and a pilot trial. An open-label, doseescalation study in 10 FA patients demonstrated increased frataxin concentrations in PBMCs to the levels of heterozygous carriers (Libri et al., 2014) . Clinical measures did not show significant changes; however, a randomized, placebo-control study with the highest dose is planned (NICOFA trial; EUDRA-CT 2017-002163-17).
Increasing frataxin expression with HDAC inhibitors is promising; however, it relies on non-specific gene activation. A recently developed strategy is the use of synthetic transcription factors targeted to the GAA repeat by polyamide PA1 to release paused RNA polymerase II into productive elongation (Erwin et al., 2017) . Another targeted strategy is the introduction of anti-GAA duplex RNAs or single-stranded locked nucleic acid (LNA) to block R-Loop formation . Indeed, in addition to the presence of triple-stranded DNA helices, which might trigger repressive chromatin (Grabczyk et al., 2007) , recent evidence suggests that the GAA tract within the nascent FXN transcript binds to genomic DNA forming R-loop, thereby impeding transcription elongation (Groh et al., 2014) . Introduction of anti-GAA duplex RNA or anti-sense oligonucleotides (ASOs) into FA-derived fibroblast cell lines led to a 2-to 6-fold increase in frataxin protein . This was associated with changes in the histone methylation and histone acetylation status at the FXN gene locus, thereby relieving heterochromatinmediated repression of the FXN gene. Importantly, experiments using single-stranded LNA demonstrated that only those ASOs complementary to the GAA have an effect . While promising, further experiments with optimized ASOs in animal models need to be conducted to study efficacy and off-target effects.
Restoration of an ARCA protein by improvement of transcription and translation is also the rationale of glucocorticoid treatment in AT. Glucocorticoids appear to induce a non-canonic splicing event in the ATM mRNA precursor, which leads to novel ATM transcripts (family of ATM dexa1 transcripts). These transcripts allow translation of a short ATM variant retaining kinase activity, thus restoring the detrimental effect of many ATM mutations (Menotta et al., 2017) . To avoid the side effects of long-term steroid administration, a method for encapsulating dexamethasone sodium phosphate into autologous erythrocytes (EryDex method) has been developed and tested in a phase II trial (Chessa et al., 2014) , now followed by a phase III trial.
Stem-Cell-Based Gene
Transfer. Hematopoietic cells, including activated lymphocytes, monocytes, and microglial precursors, have the advantage of crossing the blood-brain barrier after systemic administration and mediate the crosscorrection of ARSA enzyme in neighboring neurons and glial cells. Hematopoietic stem cell transplantation can stabilize cerebral demyelination in patients with late-onset forms of MLD (Groeschel et al., 2016) but has no impact on peripheral neuropathy. A phase 2 trial is now ongoing using hematopoietic stemcell gene therapy in presymptomatic and very early symptomatic stages of MLD (NCT01560182), showing preliminary promising results (Sessa et al., 2016) . Among patients with late-onset forms of Krabbe disease, hematopoietic stem cell transplantation can also be beneficial (Laule et al., 2018). 4.3.3 . Gene Transfer via Viral Vectors. Significant advances in the field of gene therapy via viral vectors are opening new opportunities to explore this approach in ARCAs. New vectors that cross the blood-brain barrier have better production capacity and-most importantly-show promising clinical trial results in neuromuscular diseases. A first proof of concept using adenoassociated virus (AAV) serotype rh10 expressing human frataxin in the cardiac mouse model demonstrated not only prevention but, most importantly, complete and rapid rescue of the cardiac function and associated molecular pathology (Perdomini et al., 2014) . Very recently, preclinical proof of concept for the potential of gene therapy in treating FA ganglionopathy and sensory neuropathy, even in severely affected animals, was achieved with intravenous delivery of AAV9-expressing human frataxin (Piguet et al., 2018) . Multiple academic labs, as well as the biotechnology industry, are pursuing this promising approach.
Outlook
Therapeutic strategies exemplified here for single diseases are likely to be transferable to other ARCAs that share similar mechanisms. For example, if a strategy for viral transfer of the FXN gene is successful in FA, it is likely that it can be adapted to other ARCAs with loss-of-function mutations. As access to NGS diagnostics becomes more and more routine, the genetic characterization of patients is progressing rapidly. This allows the establishment of genetically stratified cohorts that are likely to respond quite uniformly to a molecular-driven approach and to run successful trials in small cohorts as exemplified recently (Schö ls et al., 2017) . To prepare such trials, it is now of utmost importance to continue and expand the clinical networks that are establishing representative cohorts of ARCA patients and compile data on the natural disease progression and biomarkers related to pathogenesis and disease activity. With this data at hand and the promising strategies for new pharmacological approaches in the back, it is likely that new therapies will be developed for several ARCAS within the next decade.
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